Simultaneous determination of Levetiracetam and its acid metabolite (ucb L057) in serum/plasma by liquid chromatography tandem mass spectrometry

Clinical Biochemistry

Volumn 43, Issue 4-5, 2010, Pages 485-489

  Mendu, Damodara Rao ^a   Soldin, Steven J ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Levetiracetam; Levetiracetam metabolite antiepileptic drug; Tandem mass spectrometry

Indexed keywords

ACETONITRILE; DRUG METABOLITE; ETIRACETAM; FORMIC ACID; METHANOL; RITONAVIR; UCB L 057; UNCLASSIFIED DRUG; WATER;

ACCURACY; ANALYTIC METHOD; ARTICLE; CALIBRATION; CENTRIFUGE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; REACTION TIME; RELIABILITY; ROOM TEMPERATURE; SEPARATION TECHNIQUE; SUPERNATANT; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; HUMANS; PIRACETAM; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 76749105200     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.11.008     Document Type: Article

References (28)

1. Hovinga C.A. Levetiracetam: a novel antiepileptic drug. Pharmacotherapy 21 (2001) 1375-1388
2. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
3. Shorvon S., Löwenthal A., Janz D., Bileen E., and Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of Levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
4. Ben-Menachem E., and Falter U. Efficacy and tolerability of Levetiracetam 3000 mg/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
5. Betts T., Waegemans T., and Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of Levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9 (2000) 80-87
6. Wilson E.A., and Brodie M.J. New antiepileptic drugs. In: Brodie M.J., and Treiman D.M. (Eds). Modern management of epilepsy (1996), Bailliere's Clin Neurol, Bailliere's-Tindall, London 672-694
7. Patsalos P.N. Pharmacokinetic profile of Levetiracetam: toward ideal characteristics. Pharmacol. Ther. 85 (2000) 77-85
8. Glauser T.A., Mitchell W.G., Weinstock A., et al. Pharmacokinetics of Levetiracetam in infants and young children with epilepsy. Epilepsia 48 (2007) 1117-1122
9. Vermeij T., and Edelbroek P. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of Levetiracetam (ucb L059) in human serum after solid-phase extraction. J. Chromatogr. Biomed. Appl. B 662 (1994) 134-139
10. Ratnaraj N., Doheny H., and Patsalos P. A micromethod for the determination of the new antiepileptic drug Levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther. Drug Monit. 18 (1996) 154-157
11. Pucci V., Bugamelli F., Mandrioli R., Ferranti A., Kenndler E., and Raggi M. High-performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed. Chromatogr. 18 (2004) 37-44
12. Rao B., Ravi R., Shyam Sundar Reddy B., et al. A validated chiral LC method for the enantioselective analysis of Levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide on amylose-based stationary phase. J. Pharm. Biomed. Anal. 35 (2004) 1017-1026
13. Martens-Lobenhoffer J., and Bode-Boger S. Determination of Levetiracetam in human plasma with minimal sample pretreatment. J. Chromatogr. B 819 (2005) 197-200
14. Juenke J., Brown P., Urry F., and McMillin G. Drug monitoring and toxicology: a procedure for the monitoring of Levetiracetam and Zonisamide by HPLC-UVJ. Anal. Toxicol. 30 (2006) 27-30
15. Grim S.A., Ryan M., Miles M.V., et al. Correlation of Levetiracetam concentrations between serum and saliva. Ther Drug Monit 25 (2003) 61-66
16. Jain D., Subbaiah G., Sanyal M., Pal U., and Shrivastav P. Determination of levetiracetam in human plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to bioequivalence studies. Rapid Commun. Mass Spectrom 20 (2006) 2539-2547
17. Matar K.M. Quantification of Levetiracetam in human plasma by liquid chromatography-tandem mass spectrometry: application to therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis 48 (2008) 822-828
18. Guo T., Oswald L., Mendu D., and Soldin S.J. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography-electrospray tandem mass spectrometry. Clin. Chim. Acta 375 (2007) 115-118
19. Isoherranen N., Roeder M., Soback S., Yagen B., Schurig V., and Bialer M. Enantioselective analysis of Levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J. Chromatogr. 745 (2000) 325-332
20. Isoherranen N., Yagen B., Soback S., Roeder M., Schurig V., and Bialer M. Pharmacokinetic analysis of levetiracetam and its enantiomer R-alpha-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 42 (2001) 825-830
21. Pellock J.M., Glauser T.A., Bebin E.M., et al. Pharmacokinetic study of Levetiracetam in children. Epilepsia 42 (2001) 1574-1579
22. Coupez R., Nicolas J.M., and Browne T.R. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia 44 (2003) 171-178
23. Brockmöller J., Thomsen T., Wittstock M., Coupez R., Lochs H., and Roots I. Pharmacokinetics of Levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin. Pharmacol. Ther. 77 (2005) 529-541
24. Bland J.M., and Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1 (1986) 307-310
25. Perucca E., and Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs: focus on Topiromate, Levetiracetam. Relative bioavailability and bioequivalence of a 10% oral solution (750 mg). Clin. Pharmacokinet. 31 (1996) 29-46
26. Patsalos P.N., Ghattaura S., Ratnaraj N., and Sander J.W. In situ metabolism of Levetiracetam in blood of patients with epilepsy. Epilepsia 47 (2006) 1818-1821
27. Nicholas J.-M., Collart P., Gerin B., Mather G., Trager W., and Levy R Roba J. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab. Dispos. 27 (1999) 250-254
28. Radtke R.A. Pharmacokinetics of Levetiracetam. Epilepsia 42 (2001) 24-27